We investigated whether anti-CD47 antibody could enhance the efficacy of anti-GD2 antibody in neuroblastoma and other GD2+ malignancies. We demonstrate substantial synergy of these two agents, resulting in the recruitment of tumor associated macrophages (TAMs) to mediate robust and durable anti-tumor ...
Here we report updated interim results from the first-in-human phase 1 evaluation of autologous NKTs co-expressing a GD2-specific CAR with interleukin 15 (IL15) (GD2-CAR.15) in 12 children with neuroblastoma (NB). The primary objectives were safety and determination of maximum tolerated dose...
On 2 March 2015 the European Medicines Agency published its public summary of opinion on orphan designation for OGD2 Pharma chimeric monoclonal antibody to O-acetyl-GD2 antigen for the treatment of neuroblastoma granted by the European Commission on 15 January 2015 (EU/3/14/1416). “The sponsor...
1. M. Ozkaynak et al. “Phase I Study of Chimeric Human/Murine Anti–Ganglioside GD2 Monoclonal Antibody (ch14.18) With Granulocyte-Macrophage Colony-Stimulating Factor in Children With Neuroblastoma Immediately After Hematopoietic Stem-Cell Transplantation: A Children’s Cancer Group Study” Journal ...
(1989). “Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18.” Cancer Res 49(11): 2857-2861 想要了解更多信息 请点击下方按钮,...
Neuroblastoma (NBL) accounts for a disproportionate number of deaths among childhood malignancies despite intensive multimodal therapy that includes antibo
To determine the potential of anti-CCL2 inhibition as a therapy for recurrent metastatic disease in neuroblastoma, a mouse model of minimal residual disease was utilized in which residual disease was treated with anti-CCL2 monoclonal antibody with etoposide. The effect of anti-CCL2 antibody on ...
Immunotherapy with the chimeric anti-GD2 monoclonal antibody dinutuximab, combined with alternating granulocyte-macrophage colony-stimulating factor and intravenous interleukin-2 (IL-2), improves survival in patients with high-risk neuroblastoma. We aimed to assess event-free survival after treatment with...
A pilot trial of humanized anti-GD2 monoclonal antibody (hu14.18K322A) with chemotherapy and natural killer cells in children with recurrent/refractory neuroblastoma. 来自 国家科技图书文献中心 喜欢 0 阅读量: 119 作者: SM Federico,MB Mccarville,BL Shulkin,PM Sondel,JA Hank,P Hutson,M Meagher...
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results Andras Heczey Xin Xu Leonid S. Metelitsa Nature Medicine Article 15 May 2023 Sections Figures References Abstract Data availability References Acknowledgements Author information Ethics declarations Add...